Market Access
In the Belgian landscape, Market Access is shaped by a stringent regulatory and reimbursement framework, requiring strategic navigation of FAMHP for market authorization and RIZIV/INAMI for pricing and reimbursement. The system emphasizes health technology assessment (HTA), where clinical and economic value drive decision-making. The focus on cost containment, combined with evolving policies around innovation and real-world evidence, makes the Belgian landscape both challenging and dynamic, and early stakeholder engagement for companies a must.
Healixia has established a Market Access working group since 2025, in response to interest from our members. With this initiative, we aim to strengthen our members professionally by offering training and networking opportunities on different relevant Market Access topics.
We would like to capture which topics are most relevant to Market Access professionals through the short survey below. This will help us tailor our initiatives to the needs and interests of our members.
